Bayer hits back over Indian complusory licence ruling
German pharmaceutical company Bayer says it will appeal yesterday’s decision by India’s IP Appellate Board to uphold a compulsory licence granted over its cancer drug Nexavar
The Board backed an order granted last year by the then head of India’s IP Office, PH Kurian, that gave local generic drug company Natco a licence to produce a version of sorafenib, which is used to treat kidney and...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.